John P. Schmid - 23 Jul 2021 Form 4 Insider Report for Poseida Therapeutics, Inc.

Role
Director
Signature
/s/ Harry J. Leonhardt, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
23 Jul 2021
Net transactions value
$0
Form type
4
Filing time
26 Jul 2021, 20:32:38 UTC
Previous filing
17 Jun 2021
Next filing
05 Oct 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PSTX Stock Option (Right to Buy) Award $0 +25,833 $0.000000 25,833 23 Jul 2021 Common Stock 25,833 $8.63 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option will vest and become exercisable on the earlier to occur of (i) June 16, 2022 and (ii) the day preceding the date of the 2022 annual meeting of the Issuer's stockholders.